Gilead Sciences Newswire

Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 825 in Gilead Sciences

  1. 'Crohn's Disease - Pipeline Review, H1 2015' PublishedRead the original story w/Photo

    Friday | PR-inside.com

    ... zla, Ferring International Center S.A., Galapagos NV, Genentech, Inc., Genfit SA, Genor BioPharma Co., Ltd., Gilead Sciences, Inc., iCo Therapeutics Inc., Idera Pharmaceuticals, Inc., Immune Response BioPharma, Inc.,

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Friday | Business Wire

    ... y tadalafilo para la hipertensin arterial pulmonar, publicados en The New England Journal of Medicine )--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado hoy los resultados detallados del estudio AMBITION (un estudio multicentrico, doble ciego, ...

    Comment?

  3. Gilead may buy 12-acre site: Foster City Chess-Hatch office property reportedly up for saleRead the original story w/Photo

    Friday | San Mateo Daily Journal

    As one of Foster City's largest employers, Gilead Sciences may be continuing to add to its expansive real estate portfolio by picking up the nearly 12-acre Chess-Hatch office complex centrally situated along the Peninsula. The biotech pharmaceutical giant is already in the midst of expanding into its 72-acre campus off Vintage Park and has since purchased another six properties while reportedly making moves on the nearly 12-acre site along State Route 92, according to Community Development Director Curtis Banks.

    Comment?

  4. ARC Ohio gets $100,000 grant, to hire staffRead the original story w/Photo

    Thursday Aug 27 | Business Journal

    The AIDS Resource Center Ohio has won a $100,000 grant to hire new staff for an HIV prevention program. The grant comes through Gilead Sciences Inc,m and will fund two new jobs for the company, community engagement managers, one located in Columbus and the other in Dayton, for outreach to individuals at substantial risk for contracting HIV.

    Comment?

  5. Biogen And Gilead Sciences Catch The Eye Of Short SellersRead the original story w/Photo

    Thursday Aug 27 | Benzinga

    Between the July 31 and August 14 settlement dates, the number of shares short in the leading biotech and emerging pharmaceutical stocks was mixed. Short sellers were especially drawn to Biogen Inc , Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated in those two weeks.

    Comment?

  6. Gilead Release: Results From The AMBITION Study Of First-Line...Read the original story

    Wednesday Aug 26 | BioSpace

    Gilead Sciences, Inc. today announced detailed results from the AMBITION study . In AMBITION, conducted in collaboration with GlaxoSmithKline , combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm .

    Comment?

  7. Premarket Biotech Digest: CLL Treatment, Gilead CEO Sells, Acelity IPORead the original story w/Photo

    Thursday Aug 27 | Seeking Alpha

    ... ABBV ), and partially owned by Johnson & Johnson (NYSE: JNJ ), had annual sales of $730 million last year. Gilead Sciences ( GILD ) shares bounced back with the broader market on Wednesday. The stock gained more than 4% on Wednesday and is up ...

    Comment?

  8. Health ministry approves new hepatitis C drug under insurance schemeRead the original story w/Photo

    Thursday Aug 27 | The Japan Times

    A health ministry panel has added a new highly effective, but expensive, hepatitis C virus drug to the national health insurance scheme, giving high hopes for patients who have had to endure painful interferon injections. The tablet drug Harvoni, developed by U.S.-based Gilead Sciences Inc., is expected to revolutionize the treatment of patients with hepatitis C genotype 1, which accounts for about 70 percent of all hepatitis C patients in Japan.

    Comment?

  9. Why Rich Gilead Can and Should Take Over Bristol-Myers SquibbRead the original story

    Wednesday Aug 26 | BioSpace

    Gilead Sciences, Inc. has accumulated a lot of cash during its exceptional stint as leader of the hepatitis C drug market. The company is now being pressurized by investors and analysts to put its cash pile to strategic use, preferably through an accretive acquisition.

    Comment?

  10. Insider Selling: John C. Martin Sells 133,213 Shares of Gilead Sciences StockRead the original story

    Wednesday Aug 26 | AmericanBankingNews.com

    Gilead Sciences CEO John C. Martin sold 133,213 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $105.17, for a total transaction of $14,010,011.21.

    Comment?

  11. Results From the AMBITION Study of First-Line Treatment With Letairis ...Read the original story

    Wednesday Aug 26 | Benzinga

    Gilead Sciences, Inc. today announced detailed results from the AMBITION study . In AMBITION, conducted in collaboration with GlaxoSmithKline , combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm .

    Comment?

  12. Gilead Sciences Price Target Increased to $127.00 by Analysts at Morgan StanleyRead the original story

    Wednesday Aug 26 | AmericanBankingNews.com

    ... A number of other brokerages also recently commented on GILD. Argus set a $150.00 target price on shares of Gilead Sciences and gave the stock a "buy" rating in a research report on Tuesday, June 23rd. Vetr upgraded shares of Gilead Sciences from a ...

    Comment?

  13. Schizophrenia - Pipeline Review, H1 2015: New research report available at Fast Market ResearchRead the original story w/Photo

    Wednesday Aug 26 | PR-inside.com

    ... Roche Ltd., FORUM Pharmaceuticals Inc., Galenea Corp., GeNeuro SA, Genovate Biotechnology Co., LTD., Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., GP Pharm, S.A., GW Pharmaceuticals Plc, H. Lundbeck A/S, Heptares Therapeutics Limited, ...

    Comment?

  14. Premarket Biotech Digest: Valeant's M&A Prospects, Stocks Tumble, Novartis Promacta ExtensionRead the original story w/Photo

    Tuesday Aug 25 | Seeking Alpha

    ... The present environment has certainly presented VRX with an excellent opportunity. Gilead Tumbles at Open - Gilead Sciences (NASDAQ: GILD ) shares tumbled at the open on Monday as the Dow Jones dropped 1000 points amid turmoil in global markets. ...

    Comment?

  15. Gilead Sciences Given A+ Credit Rating by MorningstarRead the original story

    Tuesday Aug 25 | AmericanBankingNews.com

    Gilead Sciences has earned an "A+" credit rating from analysts at Morningstar . The research firm's "A+" rating indicates that the company is a low default risk.

    Comment?

  16. Could Geron Corporation Be The Next Big Biotech Winner?Read the original story

    Monday Aug 24 | BioSpace

    ... providing gutsy early investors with massive returns in a short amount of time. If you can buy into the next Gilead Sciences or Celgene before it makes its run, you could retire early from a modest initial investment. Of course, finding the next ...

    Comment?

  17. Prescription Drug Pricing: Give the People What They WantRead the original story

    Monday Aug 24 | The American Journal of Managed Care

    ... being targeted by a drug." Much of the current discussion around the price of pharmaceuticals was sparked by Gilead Sciences, Inc, when the company introduced the hepatitis C drug Sovaldi at an astounding $1000 per pill, or $84,000 per course of ...

    Comment?

  18. Newly released market study: Sickle Cell Disease - Pipeline Review, H1 2015Read the original story w/Photo

    Monday Aug 24 | PR-inside.com

    ... Dilaforette AB, Emmaus Medical, Inc., Errant Gene Therapeutics, LLC, Erytech Pharma SA, Gamida Cell Ltd., Gilead Sciences, Inc., Global Blood Therapeutics, Inc., Isis Pharmaceuticals, Inc., Johnson & Johnson, Morphogenesis, Inc., NKT Therapeutics, ...

    Comment?

  19. Dow plunges 900 points, TSX tumbles almost 700 points at the openRead the original story w/Photo

    Monday Aug 24 | Globe and Mail

    Earlier, U.S. index futures had signalled losses will cascade in the world's biggest stock market as contracts on the major equity indexes hit their daily loss limits of 5 per cent. In a broad selloff spanning all industries, stocks including Apple Inc. and Netflix Inc. slid at least 6 percent, while slumps in Gilead Sciences Inc. and Biogen Inc. indicated a selloff in biotechnology shares won't abate.

    Comment?

  20. At the open: TSX, Dow bloodied as global selloff intensifiesRead the original story w/Photo

    Monday Aug 24 | Globe and Mail

    ... all industries, stocks including Apple Inc. and Netflix Inc. slid at least 6 per cent, while slumps in Gilead Sciences Inc. and Biogen Inc. indicated a selloff in biotechnology shares won't abate. ConocoPhillips and Chevron Corp. lost more than 8.4 ...

    Comment?